Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: Pre-clinical studies

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Schönfeld, Kurt ^a   Zuber, Chantal ^a   Pinkas, Jan ^b   Häder, Thomas ^a   Bernöster, Katrin ^a   Uherek, Christoph ^a  

^a BIOTEST AG   (Germany)

^b IMMUNOGEN INC   (United States)

Author keywords

Drug combination; Indatuximab ravtansine; Multiple myeloma; Pre clinical; Tumour regression

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; INDATUXIMAB RAVTANSINE; LENALIDOMIDE; MELPHALAN; SYNDECAN 1; THALIDOMIDE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY; SDC1 PROTEIN, HUMAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENTIATION; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; MOUSE; PRECLINICAL STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE; MULTIPLE MYELOMA; SYNDECAN-1; THALIDOMIDE;

EID: 85009958027     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0380-0     Document Type: Article

References (9)

1. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica. 2006;91(9):1234-40.
2. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989;1(1):27-35.
3. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009;15(12):4028-37.
4. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829-44.
5. Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40(5):634-51.
6. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014;7(1):127-41.
7. Jagannath S, Chanan-Khan AA, Heffner LT, Avigan D, Zimmerman TM, Lonial S, et al. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2011;118:305.
8. Heffner LT, Jagannath S, Zimmerman TM, Lee KP, Rosenblatt J, Lonial S, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood (ASH Annual Meeting Abstracts). 2012;120:4042.
9. Kelly KR, Chanan-Khan A, Heffner LT, Somlo G, Siegel DS, Zimmerman TM, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib. Blood (ASH Annual Meeting Abstracts). 2014;124:4736.